Mason Carrico
Stock Analyst at Stephens & Co.
(1.03)
# 3,531
Out of 4,814 analysts
75
Total ratings
22.95%
Success rate
-10.76%
Average return
Main Sectors:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCYT Veracyte | Reiterates: Overweight | $45 | $31.76 | +41.69% | 7 | Mar 26, 2025 | |
| OCX OncoCyte | Reiterates: Equal-Weight | $4 | $2.84 | +40.85% | 5 | Mar 26, 2025 | |
| GH Guardant Health | Reiterates: Overweight | $55 | $45.18 | +21.74% | 5 | Mar 26, 2025 | |
| AKYA Akoya Biosciences | Downgrades: Equal-Weight | $3.5 → $1.8 | $1.10 | +63.64% | 6 | Mar 25, 2025 | |
| CTKB Cytek Biosciences | Reiterates: Overweight | $6 | $3.66 | +64.16% | 2 | Mar 19, 2025 | |
| STAA STAAR Surgical Company | Reiterates: Equal-Weight | $17 | $16.91 | +0.53% | 2 | Mar 18, 2025 | |
| ILMN Illumina | Reiterates: Overweight | $156 | $71.16 | +119.22% | 7 | Mar 11, 2025 | |
| ESTA Establishment Labs Holdings | Reiterates: Overweight | $52 | $31.58 | +64.66% | 2 | Mar 6, 2025 | |
| CDNA CareDx | Reiterates: Overweight | $40 | $17.59 | +127.40% | 9 | Feb 27, 2025 | |
| PACB Pacific Biosciences of California | Reiterates: Overweight | $2.5 | $1.17 | +113.68% | 4 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 | $57.55 | +45.96% | 3 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $14 → $13 | $13.09 | -0.69% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $20 | $7.63 | +162.12% | 4 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $41.19 | +57.82% | 1 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $41 | $21.53 | +90.48% | 7 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $7.51 | +299.47% | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $125 | $148.08 | -15.59% | 4 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $19 | $9.54 | +99.16% | 1 | Jul 30, 2024 |
Veracyte
Mar 26, 2025
Reiterates: Overweight
Price Target: $45
Current: $31.76
Upside: +41.69%
OncoCyte
Mar 26, 2025
Reiterates: Equal-Weight
Price Target: $4
Current: $2.84
Upside: +40.85%
Guardant Health
Mar 26, 2025
Reiterates: Overweight
Price Target: $55
Current: $45.18
Upside: +21.74%
Akoya Biosciences
Mar 25, 2025
Downgrades: Equal-Weight
Price Target: $3.5 → $1.8
Current: $1.10
Upside: +63.64%
Cytek Biosciences
Mar 19, 2025
Reiterates: Overweight
Price Target: $6
Current: $3.66
Upside: +64.16%
STAAR Surgical Company
Mar 18, 2025
Reiterates: Equal-Weight
Price Target: $17
Current: $16.91
Upside: +0.53%
Illumina
Mar 11, 2025
Reiterates: Overweight
Price Target: $156
Current: $71.16
Upside: +119.22%
Establishment Labs Holdings
Mar 6, 2025
Reiterates: Overweight
Price Target: $52
Current: $31.58
Upside: +64.66%
CareDx
Feb 27, 2025
Reiterates: Overweight
Price Target: $40
Current: $17.59
Upside: +127.40%
Pacific Biosciences of California
Feb 18, 2025
Reiterates: Overweight
Price Target: $2.5
Current: $1.17
Upside: +113.68%
Feb 6, 2025
Reiterates: Overweight
Price Target: $84
Current: $57.55
Upside: +45.96%
Jan 30, 2025
Downgrades: Equal-Weight
Price Target: $14 → $13
Current: $13.09
Upside: -0.69%
Jan 16, 2025
Reiterates: Equal-Weight
Price Target: $20
Current: $7.63
Upside: +162.12%
Jan 15, 2025
Reiterates: Overweight
Price Target: $65
Current: $41.19
Upside: +57.82%
Jan 2, 2025
Reiterates: Overweight
Price Target: $41
Current: $21.53
Upside: +90.48%
Oct 10, 2024
Reiterates: Overweight
Price Target: $30
Current: $7.51
Upside: +299.47%
Aug 9, 2024
Reiterates: Overweight
Price Target: $125
Current: $148.08
Upside: -15.59%
Jul 30, 2024
Reiterates: Overweight
Price Target: $19
Current: $9.54
Upside: +99.16%